It is called a targeted therapy since it specifically targets the CD38  which are overexpressed about the multiple myeloma cells. Daratumumab is from a class of medicines called CD38 monoclonal antibodies. DARZALEX® is supplied being an intravenous (IV) infusion after dilution at sixteen mg/kg of real system weight2copyright is also approved to